← Back to patent-cliff list
GXV-813
Tier C — Watch / tradeGXV-813
Novartis
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CHRM4
Indications (approved)：Schizophrenia
Regional status
US
Phase II
2026-03-16
EU
Phase II
2026-03-16
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of GXV-813?
Approved indications include: Schizophrenia.
When does the GXV-813 patent expire?
No public expiry year is available for GXV-813 yet; this page updates once verified.
How do I get a quote for GXV-813 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29